RLYB•Rallybio shareholders approved share issuance for the proposed Avenzo merger, a reverse stock split ranging from 1-for-2 to 1-for-9, and an increase in authorized common shares to 500 million.
At the November 4 annual meeting, Rallybio shareholders approved share issuance for the proposed Avenzo merger, authorized a 1-for-2 to 1-for-9 reverse stock split and increased authorized common shares from 200 million to 500 million. They also approved renaming the company Avenzo Therapeutics, elected four Class II directors, approved the 2026 Equity Incentive Plan and Employee Stock Purchase Plan contingent on merger completion, and ratified Deloitte & Touche as auditor for fiscal 2026. A proposed adjournment was not submitted for approval because it was unnecessary.
